Nurix, Inc.
Formerly Kura Therapeutics, Inc.
Nurix, Inc. is listed today as Nurix Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2020 | $120 M | No. 4 | $50 to $250 million | equity | SEC | |
| Sep 2015 | $17 M | No. 3 | $10 to $50 million | equity | SEC | |
| Dec 2013 | $2 M | No. 2 | $2 to $10 million | equity | SEC | |
| Apr 2012 | $5 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Nurix Therapeutics, Inc., its revenue in fiscal 2025 came from these product and service lines: Collaboration revenue $53.98 million (64%), License revenue $30 million (36%).
Annual report (SEC XBRL) · Nov 2025
Nurix, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2020).
SEC Form D · Mar 2020
The industry group it chose in its notices: Other.
SEC Form D · Mar 2020
Products and services#
No products or services of Nurix, Inc. are on record.
Investors#
13 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Column Group GP, LP | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, B and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Column Group II GP, LP | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, B and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Column Group II, LP | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, B and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Column Group L.P. | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, B and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Ponoi Capital II, LP | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, B and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Ponoi Capital, LP | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, B and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Ponoi II Management, LLC | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, B and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Ponoi Management, LLC | Fund or asset manager | not stated | not stated | Held Series A-1, A-2, B and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Redmile Group, LLC | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Third Rock Ventures GP III, L.P. | Venture capital | not stated | not stated | Held Series B and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Third Rock Ventures III, L.P. | Venture capital | not stated | not stated | Held Series B and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| TRV GP III, LLC | Other | not stated | not stated | Held Series B and D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | Fund or asset manager | not stated | not stated | Held Series D preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 23 investors.
Largest shareholders today
Institutions holding Nurix Therapeutics, Inc. shares, as of Sep 30, 2026.
- BlackRock, Inc.$209 M8.06%
- Redmile Group, LLC$187 M7.23%
- Vestal Point Capital, LP$167 M6.43%
- Deep Track Capital, LP$142 M5.49%
- Perceptive Advisors LLC$127 M4.92%
- Morgan Stanley$124 M4.80%
- Rubric Capital Management LP$118 M4.55%
- FMR LLC$111 M4.28%
- Baker Bros. Advisors LP$110 M4.26%
- Price T Rowe Associates Inc /MD/$108 M4.18%
- Vanguard Capital Management LLC$107 M4.12%
- State Street Corp$105 M4.05%
- General Atlantic, L.P.$72 M2.78%
- Geode Capital Management, LLC$60 M2.30%
- ARK Investment Management LLC$44 M1.70%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Arthur Sands | Executive officer | Mar 2020 |
| Christine Ring | Executive officer | Mar 2020 |
| Hans van Houte | Executive officer | Mar 2020 |
| Arthur T. Sands | Executive officer | Sep 2015 |
| Timothy Kutzkey | Executive officer | Sep 2015 |
| Mark Goldsmith | Executive officer | Jan 2014 |
| Arthur Sands | Director | Mar 2020 |
| David Lacey | Director | Mar 2020 |
| Jeff Tong | Director | Mar 2020 |
| Julia Gregory | Director | Mar 2020 |
| Leon Chen | Director | Mar 2020 |
| Lori Kunkel | Director | Mar 2020 |
| Robert Tjian | Director | Mar 2020 |
| Arthur T. Sands | Director | Sep 2015 |
| David Goeddel | Director | Sep 2015 |
| Mark Goldsmith | Director | Sep 2015 |
| Timothy Kutzkey | Director | Sep 2015 |
About
Company in San Francisco, United States.
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.